Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AvantorAVTR +2.80%61 EV-to-EBITDA is 101.01 as of Jul. 27, 2026, which is 449% above its 10-year median of 18.41. GuruFocus rates AVTR with a GF Score™ of 61/100 and a GF Value™ of $18.43 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Avantor ranks worse than 95.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Avantor's enterprise value is $11,566 Mil.
Avantor's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $115 Mil. Therefore, Avantor's EV-to-EBITDA for today is 101.01.
The historical rank and industry rank for Avantor's EV-to-EBITDA or its related term are showing as below:
AVTR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.18 Med: 18.41 Max: 101.85
Current: 101.01
During the past 10 years, the highest EV-to-EBITDA of Avantor was 101.85. The lowest was 8.18. And the median was 18.41.
AVTR's EV-to-EBITDA is ranked worse than 95.88% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.115
vs AVTR: 101.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-07-27), Avantor's stock price is $11.76.
Avantor's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.810. Therefore, Avantor's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Avantor (NYSE:AVTR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Avantor's share price for today is $11.76.
Avantor's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.810.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Avantor's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Avantor's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avantor EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avantor's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Avantor's EV-to-EBITDA falls into.
Avantor's current Enterprise Value is $11,566 Mil.
Avantor's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $115 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avantor (AVTR) has a EV-to-EBITDA of 101.01 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avantor. This is 449% above median its historical median of 18.41. Over the past decade, Avantor's EV-to-EBITDA has ranged from 8.18 to 101.85. According to the industry distribution chart, Avantor ranks #489 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 95.9%.
Is Avantor's EV-to-EBITDA too high?
Avantor's current EV-to-EBITDA of 101.01 is 449% above median its 10-year median of 18.41. Over the past 10 years, this metric has ranged from a low of 8.18 to a high of 101.85. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.12. Avantor's value of 101.01 is 615.6% above this industry median. Based on the distribution chart, Avantor ranks #489 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Avantor has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Avantor's EV-to-EBITDA compare to RGEN and ATR?
According to the Medical Devices & Instruments industry distribution chart, Avantor ranks #489 out of 510 companies for EV-to-EBITDA. This places Avantor in the lower half of its industry. The industry median EV-to-EBITDA is 14.12. Avantor's value of 101.01 is 615.6% above this benchmark. Historically, Avantor's own EV-to-EBITDA has ranged from 8.18 to 101.85 over the past decade. While the company's 10-year median is 18.41 vs. the industry median of 14.12, Avantor has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.12, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avantor's current EV-to-EBITDA of 101.01 is 615.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Avantor. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avantor's current EV-to-EBITDA is 101.01, which is 449% above median its own 10-year median of 18.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avantor stock overvalued right now?
Based on GuruFocus' analysis, Avantor (AVTR) is currently considered Possible Value Trap. The stock's GF Value™ is $18.43, compared to a current price of $11.76 — trading 36.2% below its estimated fair value. The current EV-to-EBITDA is 101.01, which is 449% above median its 10-year median of 18.41 and 615.6% above the Medical Devices & Instruments industry median of 14.12. Avantor's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Avantor (AVTR), the current EV-to-EBITDA is 101.01 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avantor (AVTR) Overvalued in 2026?
Based on GuruFocus' analysis, Avantor stock appears to be undervalued.
The current stock price of $11.76 is trading 36.2% below its estimated GF Value™ of $18.43.
GuruFocus considers Avantor to be Possible Value Trap.
Key valuation signals for AVTR:
EV-to-EBITDA: 101.01 (449% above median its 10-year median of 18.41)
GF Value™: $18.43 vs. price of $11.76 (36.2% below fair value)
Industry Position: 615.6% above the Medical Devices & Instruments median (#489 of 510)
No single metric tells the full story. See the AVTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
61GF Score
Get the complete analysis for AVTR
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVTR has been successfully added to your 
